Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.